Summary
Abstract The same intensity applied to identifying molecular targets, investing in research, and running clinical trials that is occurring now for adult cancers has not extended to the pediatric population, despite evidence that doing so in pediatric cancers will improve patient outcomes. An amenable context for targeted therapies is fusion- driven cancers, which are characterized by relatively quiet genomes with recurrent, balanced translocations that create fusion oncoproteins that drive oncogenesis. CIC::DUX4 sarcoma, a common member of the Ewing sarcoma family of pediatric and young adult
